Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's executive management will deliver a corporate overview presentation on Tuesday, August 12, 2025, at 12:30 p.m. Eastern time.
Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website at ir.castlebiosciences.com/events-presentations/. A replay of the presentation will be made available after the event.
Castle Biosciences (Nasdaq: CSTL), un'azienda sanitaria specializzata in test diagnostici innovativi, ha annunciato la sua partecipazione alla prossima 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il management esecutivo dell'azienda presenterà una panoramica aziendale martedì 12 agosto 2025, alle 12:30 ora orientale.
Investitori e interessati potranno seguire la diretta audio in streaming tramite il sito web delle relazioni con gli investitori di Castle Biosciences all'indirizzo ir.castlebiosciences.com/events-presentations/. Una registrazione della presentazione sarà disponibile dopo l'evento.
Castle Biosciences (Nasdaq: CSTL), una empresa de salud especializada en pruebas diagnósticas innovadoras, ha anunciado su participación en la próxima 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. La alta dirección de la compañía ofrecerá una presentación general corporativa el martes 12 de agosto de 2025 a las 12:30 p.m., hora del este.
Los inversores y partes interesadas podrán acceder a la transmisión de audio en vivo a través del sitio web de relaciones con inversores de Castle Biosciences en ir.castlebiosciences.com/events-presentations/. Una repetición de la presentación estará disponible después del evento.
Castle Biosciences (나스닥: CSTL)는 혁신적인 진단 테스트를 전문으로 하는 헬스케어 기업으로, 다가오는 Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2025년 8월 12일 화요일 동부 표준시 기준 오후 12시 30분에 기업 개요 발표를 진행할 예정입니다.
투자자 및 관심 있는 분들은 Castle Biosciences 투자자 관계 웹사이트 ir.castlebiosciences.com/events-presentations/를 통해 라이브 오디오 웹캐스트를 시청할 수 있습니다. 발표 후에는 다시보기 서비스도 제공됩니다.
Castle Biosciences (Nasdaq : CSTL), une entreprise de santé spécialisée dans les tests diagnostiques innovants, a annoncé sa participation à la prochaine 45e Conférence Annuelle de Croissance Canaccord Genuity. La direction exécutive de la société présentera un aperçu de l'entreprise le mardi 12 août 2025 à 12h30, heure de l'Est.
Les investisseurs et les parties intéressées pourront accéder à la diffusion audio en direct via le site web des relations investisseurs de Castle Biosciences à l'adresse ir.castlebiosciences.com/events-presentations/. Un replay de la présentation sera disponible après l'événement.
Castle Biosciences (Nasdaq: CSTL), ein Gesundheitsunternehmen, das sich auf innovative diagnostische Tests spezialisiert hat, hat seine Teilnahme an der bevorstehenden 45. jährlichen Wachstumskonferenz von Canaccord Genuity angekündigt. Das Führungsteam des Unternehmens wird am Dienstag, den 12. August 2025, um 12:30 Uhr Eastern Time eine Unternehmensübersicht präsentieren.
Investoren und Interessierte können den Live-Audio-Webcast über die Investor-Relations-Website von Castle Biosciences unter ir.castlebiosciences.com/events-presentations/ verfolgen. Eine Aufzeichnung der Präsentation wird nach der Veranstaltung verfügbar sein.
- None.
- None.
FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) presenting at the Canaccord Genuity Conference?
How can investors access Castle Biosciences' (CSTL) Canaccord conference presentation?
What will Castle Biosciences (CSTL) discuss at the Canaccord Growth Conference?
Will there be a replay available of Castle Biosciences' (CSTL) Canaccord presentation?
